Hims & Hers Health has gone from one of the most compressed, short-heavy setups in health care to a week-long short squeeze in everything but name — the stock is up 23% on the week and 59% in a month, and the bears who refused to budge ahead of June 11 earnings are now sitting on significant losses.
The shift in the lending market tells the clearest story of how fast conditions have changed. For the entire month leading into earnings, availability was pinned at zero — every share in the lending pool was out on loan. That is no longer true. Availability has jumped to 20% of short interest, its highest reading in at least 30 days, as shorts who were unable to exit before the print have been forced to cover into the rally. Short interest has dropped to 26.9% of the free float — still one of the heaviest short books among mid-cap health care names, but down from 28.5% just a week ago and from a peak near 30% in early May. About 3.5 million shares have been covered in the past five days alone. Cost to borrow has actually softened rather than spiked in this environment, easing to 0.94% from around 1.29% pre-earnings, which suggests the squeeze pressure is coming from price action rather than a further tightening of the lending pool. The ORTEX short score holds near 68.9 — barely moved despite the covering — which means the bears have trimmed at the margin but not capitulated.
Options positioning has shifted meaningfully since the neutral read documented before earnings. The put/call ratio has edged up to 0.60, running about 1.6 standard deviations above its 20-day average of 0.56 — the most defensive lean since early May, and a notable change from the call-heavy setup that characterised the pre-earnings period. With the stock now at $35.47, options traders appear to be hedging gains or expressing caution about the sustainability of the move, rather than chasing further upside. The PCR remains well below its 52-week high of 1.52, so this is not outright bearish — it is more like the market's way of saying the easy money has been made.
The Street has been caught leaning the wrong way. Barclays raised its target to $39 on June 18 — the freshest and most consequential analyst move of the week — while maintaining its Overweight rating, acknowledging the stock has already blown through the $29 target it carried into earnings. JPMorgan carries an Overweight with a $33 target, now below the current price. Needham's Buy-rated target of $35 is essentially at the market. By contrast, BofA has been trimming its Neutral target repeatedly through May and most recently to $25, and Truist holds at $23 on Hold — both meaningfully below where the stock is trading. The mean consensus target across the panel is $27.32, which now sits roughly 23% below the close, an unusual configuration that reflects how thoroughly the rally has outrun the Street's models. The bull case rests on the Novo Nordisk partnership and strong projected revenue growth; the bear case cites execution risk, regulatory exposure around compounding practices, and competition in the telehealth market.
One angle that cuts against the post-earnings euphoria is insider behaviour. On June 15 — the day the stock was running through $30 — CEO and founder Andrew Dudum sold 85,632 shares at $30.17 for roughly $2.6 million. The COO and CTO both sold on June 17 as the stock pushed toward $32. These are relatively modest sales in aggregate, and some may be plan-driven, but the timing means the company's most senior executives were active sellers into the same rally that has left external shorts scrambling to cover. Net insider activity over 90 days is slightly positive at roughly 433,000 shares and $13 million in value — driven by equity awards rather than open-market purchases — so the overall insider picture is mixed rather than clearly bearish.
The next scheduled event is Q2 earnings on August 3. Between now and then, the key question is whether the 26.9% short float — still a substantial position — continues to unwind gradually or digs back in at the new, higher price level as bearish conviction reasserts itself around the compounding revenue outlook.
See the live data behind this article on ORTEX.
Open HIMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
